Skip to content
Peptidepedia

SS-31 (Elamipretide) Research: Clinical Studies, Evidence & Scientific Review (2026)

From Peptidepedia, the trusted peptide wiki.

Research Evidence

SS-31 has accumulated a clinical trial dataset that, while modest in size, is substantially more robust than most peptides currently in use within the biohacking community.

EMBRACE-STEMI Trial

The EMBRACE-STEMI (Evaluation of Myocardial Effects of Bendavia for Reducing Reperfusion Injury in Patients With AMI) Phase 2a trial enrolled patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction. A single intravenous infusion of 0.05 mg/kg was administered before reperfusion. The primary endpoint of infarct size reduction was not met in the overall population, but subgroup analyses suggested potential benefits in patients with anterior infarctions, a higher-risk subgroup with greater myocardial mass at risk.

PROGRESS-HF Trial

The PROGRESS-HF trial examined elamipretide in patients with heart failure with reduced ejection fraction. The trial demonstrated improvement in left ventricular end-systolic volume with trends toward improved cardiac function, though primary endpoints were not achieved. The mechanistic rationale, that chronic heart failure involves progressive mitochondrial dysfunction, remains scientifically sound and continues to motivate further research in this indication.

Barth Syndrome, TAZPOWER Trial

Barth syndrome is a rare X-linked mitochondrial disease caused by mutations in the tafazzin gene, resulting in abnormal cardiolipin composition. The TAZPOWER trial evaluated elamipretide in patients with Barth syndrome and demonstrated clinically meaningful improvements in 6-minute walk distance and cardiac function. This represents the most positive clinical trial result for SS-31 and provided the basis for its Rare Pediatric Disease and Orphan Drug designations.

Primary Mitochondrial Myopathy

A randomized dose-escalation trial published in Neurology (Karaa et al., 2018) examined elamipretide in adults with primary mitochondrial myopathy. The trial showed improvements in functional capacity measures and was well-tolerated across the dose range studied, providing safety and preliminary efficacy data in a mitochondrial disease population.

Preclinical Evidence

Preclinical research in rodent and canine models has demonstrated protective effects of SS-31 across multiple systems:

  • Cardiac: Protection against age-related diastolic dysfunction; preserved systolic function in canine heart failure models
  • Renal: Reduced injury from ischemia-reperfusion in acute kidney injury models
  • Skeletal muscle: Attenuation of age-related sarcopenia and disuse atrophy
  • Neurological: Protection against mitochondrial dysfunction in neurodegeneration models

The preclinical dataset across these systems is extensive and mechanistically coherent, providing a strong rationale for continued clinical investigation.

Frequently Asked Questions

They are the same compound. SS-31 is the original research designation used in preclinical and early clinical studies. Elamipretide is the International Nonproprietary Name (generic pharmaceutical name) assigned as the compound advanced through clinical development. Bendavia and MTP-131 are additional names used across different clinical trial programs.

Oral bioavailability is significantly reduced compared to subcutaneous injection. While oral formulations have been explored, subcutaneous administration remains the preferred route for consistent absorption. Injectable forms are standard in both clinical trials and community use.

Cycling necessity is not scientifically established. Clinical trials used continuous dosing for up to 36 weeks without apparent tolerance development. Some users implement 8-weeks-on, 4-weeks-off protocols precautionally, but this practice is not supported by clinical evidence.

Clinical trials lasting up to 36 weeks have not revealed significant safety concerns. No serious adverse events have been definitively attributed to SS-31 in published trials. However, long-term safety data in healthy populations remains limited, and individuals sourcing SS-31 from unregulated research chemical suppliers face contamination risks.

Formal drug interaction studies are lacking. Theoretically, SS-31 may complement other mitochondrial support compounds including NAD+ precursors, CoQ10/Ubiquinol, and PQQ. It has also been combined with BPC-157 for enhanced tissue healing. Starting with SS-31 alone before adding other compounds is advisable to establish individual response and tolerability.

Clinical research has focused on heart failure with reduced ejection fraction, ST-elevation myocardial infarction (ischemia-reperfusion injury), Barth syndrome, and primary mitochondrial myopathy. Preclinical evidence suggests potential applications in renal ischemia-reperfusion injury, skeletal muscle atrophy, neurodegenerative processes, and age-related mitochondrial decline.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014;171(8):2029-2050.
  2. Birk AV, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol. 2013;24(8):1250-1261.
  3. Daubert MA, et al. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. Circ Heart Fail. 2017;10(12):e004230.
  4. Butler J, et al. Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. J Card Fail. 2020;26(5):429-437.
  5. Thompson R, et al. Current and future treatment approaches for Barth syndrome. J Inherit Metab Dis. 2022;45(1):17-28.
  6. Karaa A, et al. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. 2018;90(14):e1212-e1221.
  7. Stealth BioTherapeutics. Elamipretide Development Program.
  8. Sabbah HN, et al. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016;9(2):e002206.
  9. Gibson CM, et al. EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention. Eur Heart J. 2016;37(16):1296-1303.
←Read the full SS-31 (Elamipretide) guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”